Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBT Margin (2020 - 2025)

GeneDx Holdings (WGS) has disclosed EBT Margin for 6 consecutive years, with 15.07% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 2073.0% to 15.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.94%, a 1229.0% increase, with the full-year FY2025 number at 4.94%, up 1229.0% from a year prior.
  • EBT Margin was 15.07% for Q4 2025 at GeneDx Holdings, down from 6.33% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 6393.49% in Q2 2021 to a low of 503.13% in Q4 2022.
  • A 5-year average of 204.14% and a median of 57.56% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -676624bps in 2022, then skyrocketed 45753bps in 2023.
  • GeneDx Holdings' EBT Margin stood at 69.52% in 2021, then plummeted by -624bps to 503.13% in 2022, then soared by 91bps to 45.6% in 2023, then skyrocketed by 112bps to 5.66% in 2024, then plummeted by -366bps to 15.07% in 2025.
  • Per Business Quant, the three most recent readings for WGS's EBT Margin are 15.07% (Q4 2025), 6.33% (Q3 2025), and 10.29% (Q2 2025).